StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Browse signals
PGENBullishEarningsnews
High materiality8/10

Precigen posts Q2 profitability on PAPZIMEOS with expanding adoption

Aug 4, 2026, 4:04 PM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting

The quarterly profitability milestone, robust PAPZIMEOS revenue, substantial cash runway, and long exclusivity junto with payer coverage suggest a re-rating potential near-term. Historical biotech launches show stock appreciation on profitability inflection points and strong payer support, with EMA/EMA-driven clears often triggering additional upside.

AI summary

What happened, with direct paths to the underlying reporting

Precigen reported Q2 2026 PAPZIMEOS net revenue of $53.1M, helping total revenue reach $55.0M and delivering quarterly profitability. With $38.7M cash at 6/30/2026 and guidance for cash flow break-even by year-end, management highlighted broad payer coverage and 500+ patient hub enrollments, plus seven-year FDA exclusivity; EMA review and PRGN-2009 updates add optionality.

  • PAPZIMEOS Q2 net revenue $53.1M; profitability achieved.
  • Cash, cash equivalents, investments: $38.7M as of 6/30/2026; break-even by year-end.
  • PAPZIMEOS patient hub enrollment exceeds 500; expanding US adoption.
  • FDA grants PAPZIMEOS seven-year market exclusivity; J-code J3404 in effect.
  • EMA validation and MAA under review; PRGN-2009 updates expected by year-end.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Related signals

More source-backed signals connected by company or event